Expresión de CD10 y del marcador de carcinoma renal en el carcinoma renal de células claras: Análisis en matrices tisulares

Ortiz-Rey, J.A.; María, C. Gómez de; Boismorand, E. Peláez; Costas, A. Fernández; Barreiro, M.J. Barbosa; Badiola, I. Antón

doi:10.1016/s0210-4806(06)73440-4

Cited by 2 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, 100% of primary ccRCCs were angptl4 -positive whereas 93.8% of primary non-ccRCC renal tumors were angptl4 -negative (p = 1.5 10 −49 , Chi-square test). By comparison, the expression of CD10 for primary ccRCC is reported between 75% to 82%, and is also detected in other subtypes of RCC [11], [13]. Similarly, CA9, a hypoxia-inducible protein, and Pax-2, a homeogene strongly expressed during kidney development, are expressed in a high proportion of ccRCCs but their expression is not limited to ccRCC [10], [12].…”

Section: Discussionmentioning

confidence: 98%

“…Since RCC subtypes have different malignant potential, prognoses and optimal therapies [10], many markers have been tested to support an accurate histological classification, including CD10, RCC marker (RCCma), CK7, CD117, CA9 and AMACR. Unfortunately, none of these markers is to date specific for one subtype of renal epithelial tumor [10], [11], [12], [13]. Different panels of markers for differential diagnosis of renal epithelial tumors have also been proposed [14], [15].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Determination of Angptl4 mRNA as a Diagnostic Marker of Primary and Metastatic Clear Cell Renal-Cell Carcinoma

et al. 2010

View full text Add to dashboard Cite

BackgroundWe have previously shown that angiopoietin-like 4 (angptl4) mRNA, a hypoxia-inducible gene, is highly expressed in clear cell renal-cell carcinoma (ccRCC), the most common subtype of RCC for which no specific marker is available. We here investigated whether angptl4 mRNA 1) could be a useful diagnostic and/or prognostic marker of ccRCC in a large and comprehensive retrospective series, 2) induction is dependent on the VHL status of tumors.Methodology/Principal FindingsUsing in situ hybridization, we report that angptl4 mRNA is expressed in 100% of both sporadic (n = 102) and inherited (n = 6) primary ccRCCs, without any statistical association with nuclear grade (p = 0.39), tumor size (p = 0.09), stage grouping (p = 0.17), progression-free survival (p = 0.94), and overall survival (p = 0.80). Angptl4 mRNA was also expressed in 26 (87%) of 30 secondary ccRCCs but neither in any other secondary RCCs (n = 7). In contrast, angptl4 mRNA was neither expressed in 94% non-ccRCC renal tumors (papillary RCCs (n = 46), chromophobe RCCs (n = 28), and oncocytomas (n = 9)), nor in non-renal clear cell carcinomas (n = 39). Angptl4 expression was also examined in tumors associated (n = 23) or not associated (n = 66) with VHL disease. 40 (98%) hemangioblastomas expressed angptl4 whereas all pheochromocytomas (n = 23) and pancreatic tumors (n = 25) were angptl4-negative, whatever their VHL status.Conclusions/SignificanceAngptl4 mRNA expression was highly associated with ccRCC (p = 1.5 10−49, Chi square test) allowing to define its expression as a diagnosis marker for primary ccRCC. Moreover, angptl4 mRNA allows to discriminate the renal origin of metastases of clear-cell carcinomas arising from various organs. Finally, inactivation of VHL gene is neither necessary nor sufficient for angptl4 mRNA induction.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Determination of Angptl4 mRNA as a Diagnostic Marker of Primary and Metastatic Clear Cell Renal-Cell Carcinoma

et al. 2010

View full text Add to dashboard Cite

show abstract

Tumor Necrosis Factor Receptor Expression and Signaling in Renal Cell Carcinoma

Al‐Lamki

Sadler

Wang

et al. 2010

The American Journal of Pathology

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (ccRCC), a tubular epithelial cell (TEC) malignancy, frequently secretes tumor necrosis factor (TNF). TNF signals via two distinct receptors (TNFRs). TNFR1, expressed in normal kidney primarily on endothelial cells, activates apoptotic signaling kinase 1 and nuclear factor-B (NF-B) and induces cell death, whereas TNFR2, inducibly expressed on endothelial cells and on TECs by injury, activates endothelial/epithelial tyrosine kinase (Etk), which trans-activates vascular endothelial growth factor receptor 2 (VEGFR2) to promote cell proliferation. We investigated TNFR expression in clinical samples and function in short-term organ cultures of ccRCC tissue treated with wild-type TNF or specific muteins selective for TNFR1 (R1-TNF) or TNFR2 (R2-TNF). There is a significant increase in TNFR2 but not TNFR1 expression on malignant TECs that correlates with increasing malignant grade. In ccRCC organ cultures, R1-TNF increases TNFR1, activates apoptotic signaling kinase and NF-B, and promotes apoptosis in malignant TECs. R2-TNF increases TNFR2, activates NF-B, Etk, and VEGFR2 and increases entry into the cell cycle. Wild-type TNF induces both sets of responses. R2-TNF actions are blocked by pretreatment with a VEGFR2 kinase inhibitor. We conclude that TNF, acting through TNFR2, is an autocrine growth factor for ccRCC acting via Etk-VEGFR2 cross-talk, insights that may provide a more effective therapeutic approach to this disease.

show abstract

Expresión de CD10 y del marcador de carcinoma renal en el carcinoma renal de células claras: Análisis en matrices tisulares

Cited by 2 publications

References 23 publications

Determination of Angptl4 mRNA as a Diagnostic Marker of Primary and Metastatic Clear Cell Renal-Cell Carcinoma

Determination of Angptl4 mRNA as a Diagnostic Marker of Primary and Metastatic Clear Cell Renal-Cell Carcinoma

Tumor Necrosis Factor Receptor Expression and Signaling in Renal Cell Carcinoma

Contact Info

Product

Resources

About